Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Karyopharm Absorbs Selinexor AML Blow, Focuses On Other Cancers

Executive Summary

Upcoming Phase II in diffuse large B-cell lymphoma offers opportunity for a rebound after single agent selinexor disappoints in SOPRA study of acute myeloid leukemia.

You may also be interested in...



Karyopharm’s Selinexor: US FDA Unconvinced By Efficacy In Single-Arm Trial

Oncologic Drugs Advisory Committee will consider whether approval for Karyopharm’s proposed refractory myeloma therapy selinexor should await results from an ongoing Phase III randomized trial.

New Mechanism And Oral Activity Underline Selinexor's Role In Multiple Myeloma

Karyopharm has reported positive top-line Phase IIb data from the STORM study showing the potential benefits of its orally active lead compound, selinexor, in "penta-refractory" multiple myeloma, and is aiming for rapid approval of the first-in-class agent in the US and Europe.

New Drugs Aim To Move Needle In Tough-to-Treat Acute Myeloid Leukemia

Response rates for candidates from Stemline, Seattle Genetics and Karyopharm look highly encouraging, but the real test in AML will be survival, as the field is still in the shadow of Pfizer's failed Mylotarg.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PL007508

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel